Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of a mixture of modified glucose polymers for reducing tumor metastasis

A technology for tumor metastasis and composition, which can be used in anti-tumor drugs, active ingredients of hydrocarbon compounds, medical preparations containing active ingredients, etc., and can solve problems such as harmfulness

Pending Publication Date: 2017-09-26
FRESENIUS KABI DEUT GMBH
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these results cannot be easily transferred to clinical practice because processing at 45 °C is detrimental to normal tissue cells in patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a mixture of modified glucose polymers for reducing tumor metastasis
  • Use of a mixture of modified glucose polymers for reducing tumor metastasis
  • Use of a mixture of modified glucose polymers for reducing tumor metastasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Overview: Adult female BALB / c nude mice were treated with human colon adenocarcinoma LS174T ( CL-188 TM ) after inoculation with saline, icodextrin (4%), alone or in combination with 4% icodextrin solution Blood volume surrogate (10%) and a single i.p. injection of a solution containing 10% HES 130 / 0.4 dissolved in 4% icodextrin solution were treated to determine tumor cell growth and body weight during the course of the experiment.

[0134] substance:

[0135] Saline (0.9% NaCl) (Lot No. 134002, B. Braun Melsungen AG, Melsungen, Germany) was used as a control. Test articles containing hydroxyethyl starch (HES) Blood volume substitute (10%) (poly(O-2-hydroxyethyl) starch (HES 130 / 0.4) 100 g / L, NaCl 9 g / L) (batch number 14FC3308) was purchased from Fresenius Kabi as a ready-to-use product Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany). 4% icodextrin (40g / L, sodium chloride 5.4g / L, sodium lactate 4.5g / L, calcium chloride 257mg / L, magnesium chloride 61mg / L)...

Embodiment 2

[0152] Overview: Adult female BALB / c nude mice were treated with human colon adenocarcinoma LS174T ( CL-188 TM ) after inoculation, with saline, icodextrin (4%), icodextrin (7.5%) alone Single i.p. injections of 10%, or different combinations of HES130 / 0.4 and icodextrin were treated to determine tumor cell growth and body weight over the course of the experiment.

[0153] substance:

[0154] Saline (0.9% NaCl) (Lot No. 1440030, B. Braun Melsungen AG, Melsungen, Germany) was used as a control. Test articles containing hydroxyethyl starch (HES) 10% (poly(O-2-hydroxyethyl) starch (HES130 / 0.4) 100g / L, NaCl 9g / L) (batch number 14FC3308) was purchased from Fresenius Kabi Germany Co., Ltd. (Fresenius Kabi Deutschland) as a ready-to-use product GmbH) (Bad Homburg, Germany). 4% icodextrin (40g / L, sodium chloride 5.4g / L, sodium lactate 4.5g / L, calcium chloride 257mg / L, magnesium chloride 61mg / L) (batch number 13892004, Baxter AG, (Austria, Vienna)) and 7.5% icodextrin (75g / L, ...

Embodiment 3

[0168] Example 3: Overview

[0169] Figure 11 A compilation of the data obtained in Examples 1 and 2 is shown. To make the data comparable, the total PCI value for the control (saline) was set at 100% and other values ​​were expressed as % of the control. As will be appreciated, solutions containing up to 5% icodextrin and up to 10% HES were shown to provide improved protection from tumor cell nesting compared to both the control and solutions containing a single polysaccharide. Further increasing the icodextrin concentration to above 7.5% and / or increasing the HES concentration to 20% resulted in no further improvement. Although the solution containing 7.5% icodextrin did not increase the protective effect compared to the 4% icodextrin solution, it was still effective compared to the administration of the control solution. Without wishing to be bound by theory, it can be concluded from these data that the protective effect may not be due to the osmotic (hypertonic) effect...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HAS), wherein the icodextrin is present at a concentration of from 1 to 7.5 % (w / v) and wherein said HAS is present at a concentration of from 1 to 15 % (w / v). The present invention further relates to the aforesaid pharmaceutically acceptable solution for use as a medicament and for use in (e.g., in methods of) preventing metastasis formation and / or relapse by administration to a body cavity of a subject afflicted with cancer. The present invention further relates to a kit comprising icodextrin and HAS in pre- weighed amounts and a pharmaceutically acceptable means of dissolving the same, to a device comprising a pharmaceutically acceptable solution of the present invention and means for administering the same, as well as to a pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch at a total concentration in the range of from 1 to 20 % (w / v), wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.05:1 to 5:1, for use in preventing metastasis formation and / or relapse by administration to a body cavity of a subject afflicted with cancer.

Description

technical field [0001] The present invention relates to a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HSS), wherein said icodextrin is present in a concentration of 1% to 7.5% (w / v), And wherein said HAS is present at a concentration of 1% to 15% (w / v). The present invention also relates to the use of the above-mentioned pharmaceutically acceptable solution as a medicament, and for the prevention of tumor metastasis formation and / or recurrence by administration to the body cavity of a subject suffering from cancer. The present invention also relates to a kit comprising pre-weighed amounts of icodextrin and HAS and a pharmaceutically acceptable means (i.e. diluent) for dissolving them; to a device comprising a pharmaceutically acceptable solution of the invention and a means for its administration ; also relates to a pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch in a total c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/718A61K31/716A61P35/04A61P35/00
CPCA61K31/716A61K31/718A61K2300/00A61K9/08A61K31/01A61K31/721A61K31/724A61P35/00A61P35/04
Inventor 柏恩德·森德曼拉斯·沃尔兹西尔克·巴斯尼尔弗兰克·诺肯克里斯托弗·迈耶
Owner FRESENIUS KABI DEUT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com